42
2text: 粗体英文词汇附有中文释义喔～
Merck continues to build the case for the pulmonary arterial hypertension drug that won FDA approval in 2024.
In high-risk patients with pulmonary arterial hypertension(PAH), Merck’s fusion protein therapeutic Winrevair reduced the likelihood of major morbidity and mortality by 76% in the Phase III ZENITH trial.
Analysts at Guggenheim Partners called this outcome “striking” and “very impressive” in a note to investors Monday, pointing to improvements in key secondary outcomes in overall survival and transplant-free survival.
The Guggenheim analysts also pointed out that Winrevair had “relatively consistent improvements” in mortality and morbidity across patient subgroups, including age, sex and disease subtype and severity.
In November 2024, Merck announced that, following the recommendations of an independent data monitoring board, it was stopping ZENITH ahead of schedule due to “overwhelming efficacy.” On Monday, the pharma revealed that in the Winrevair arm, 17.4% of patients experienced at least one major morbidity or mortality event, as opposed to 34.7% of placebo comparators.
The data were (这里误读为was) presented at the 2025 American College of Cardiology’s Annual Scientific Session and Expo and simultaneously published in The New England Journal of Medicine.
Winrevair is a recombinant activin receptor type II A-Fc fusion protein that targets and binds to activin A and other ligands that belong to the TGF-β superfamily. This mechanism of action allows Winrevair to restore balance to vascular proliferation, a key pathway that is altered in PAH. In particular, PAH patients see high excessive cell proliferation in key arteries, leading to thickened blood vessel walls and, in turn, impaired blood flow.
Winrevair was approved by the FDA to treat PAH in March 2024, making it the first-ever drug for the disease that targets activin signaling.
Merck continues to build its evidence base for Winrevair. In March 2023, the pharma unveiled full data from the Phase III STELLAR trial, touting a 40.8-meter improvement in 6-minute walk distance in patients with PAH following treatment with the drug. Winrevair also cut the risk of death or clinical worsening by 84% versus placebo.
Merck is also running the Phase III HYPERION study to assess the benefit of Winrevair when used with background therapy. In January 2025, the company ended the trial ahead of schedule, in line with the recommendations of an external committee, because of strong efficacy findings in an interim analysis. Results from HYPERION will be presented later this year, according to Merck’s Monday announcement.
原文链接：www.biospace.com
药物原理：
Sotatercept 商品名为 Winrevair，是一种融合蛋白，由 human activin receptor type IIA（ACTRIIA）的胞外结构域和人类免疫球蛋白 G1 的 Fc 结构域组成。索塔特肽（Sotatercept）作为一种配体陷阱发挥作用，能够捕获 TGFβ 超家族的成员，从而恢复促增殖的 ACTRIIA 通路与抗增殖的 BMPR2 通路之间的平衡。
Ghofrani, HA., Gomberg-Maitland, M., Zhao, L. et al. Mechanisms and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 22, 105–120 (2025). doi.org
词汇：pulmonary adj.肺的；arterial adj.[解剖] 动脉的；hypertension n.高血压；morbidity n.发病率；mortality n.死亡率；placebo n.安慰剂；comparator n.对照组；thicken v.变厚；unveil v.公开；tout v.吹捧；interim n.阶段性成果
欢迎大家在评论区与我互动，给我写邮件1978500617@qq.com，或加入听友群 Daily Life Science group 1
欢迎大家关注我的小宇宙读书播客《启真书汇》，将陆续更新政治历史、经济金融、管理学、哲学、心理学和社会学等书籍的深度解读，月更。
欢迎大家关注我的微信公众号《思无涯-Gilly》，代谢与免疫前沿研究文献深度解读，月更。
本期制作：Gilly
热爱可抵岁月漫长～
